Evotec participates in Centauri Therapeutics' Series A investment round

  • Evotec SE, together with Boehringer Ingelheim Venture Fund, and Novo Holdings REPAIR Impact Fund invested in Centauri Therapeutics Limited („Centauri“) GBP 24 m (c. US$ 32 m) Series A investment round. Founded by Animatrix Founders LLP, Centauri is an immunotherapy company focused on the treatment of infectious diseases. Additionally to the investment, Karen Lackey, Evotec’s Global Head of Integrated Drug Discovery will join Centauri’s Board of Directors.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-participates-in-centauri-therapeutics-series-a-investment-round-6145

    Du magst vielleicht auch